FOR IMMEDIATE RELEASE
Results of intelligent, wireless, left-heart, implantable, hemodynamic monitor will be presented at the Heart Failure Conference in Sevilla, Spain (May 23-26, 2015)
Michigan, USA, May 20, 2015: Integrated Sensing Systems, Inc. (ISS) announced today that results of its miniature, intelligent, wireless, left-heart, implantable, hemodynamic monitor (IHM) will be presented at the Heart Failure Conference – 2nd World Congress on Acute Heart Failure. This prestigious conference is sponsored by European Society of Cardiology (ESC) in Sevilla, Spain (May 23-26, 2015):
The oral presentation, entitled “An Implantable Hemodynamic Monitor for Long Term Wireless Monitoring of Left Heart Function,” will be presented by Dr. Jacek Baranowski (Linkoping University Hospital, Linkoping, Sweden) on May 24,2015 at the 8:30-10:00 a.m. session in Room Sevilla. Additionally, Integrated Sensing Systems will have a booth (D-40) at the Exhibition Hall.
ISS is conducting two clinical investigational studies: (1) monitoring left-heart (left atrium or left ventricle) hemodynamics to improve the long-term treatment of congestive heart failure (CHF) patients, and (2) monitoring the left atrium to improve the safety and treatment of LVAD patients.
ISS’ Titan IHM implant has been designed to monitor the filling pressure, heart rate, rhythm and pressure waveforms of the left side of the heart. The main goal of the individualized custom treatment for heart failure patients is to maintain a fine balance between improving cardiac output (blood flow pumped by a ventricle) and sustaining a reasonable left-heart filling pressure. Therefore, left-heart pressure waveforms are the most desirable parameters for the management of patients with cardiovascular problems, since unlike using pulmonary artery pressures, left filling pressure is not adversely affected by common pulmonary comorbidities such as pulmonary embolism. Monitoring the left heart is, however, very challenging due to the stringent biocompatibility and hemodynamic requirements of the left heart.
ISS is developing two categories of products: IHM sensors that are implanted adjunct to a planned thoracic surgery and implants that are delivered percutaneously via catheter-based techniques in either the pulmonary artery (PA) or left atrium during a stand-alone procedure. Titan IHM is composed of three components: a Telemetric Implant, a Monitoring Unit, and the Database Management system for internet-based worldwide access.
Dr. Baranowski, stated that, “the wireless left-heart implantable hemodynamic monitor we are studying in Sweden has shown a potential for a broad spectrum of applications. The feed-back from IHM has been used for tailoring the medical treatment of heart failure and for differentiating the systolic and diastolic predominance in CHF exacerbations. The efficacy of mitral interventions and A-fib ablations can be validated better. Also a new insight in types of atrial arrhythmias is provided. Treatment of hypertension in patients with A-fib with a feed-back from the left-heart IHM is another promising application.”
ISS is a leader in advanced MEMS technologies for design and manufacturing of medical devices. Founded in 1995, ISS is one of the oldest independent medical MEMS companies in the United States. ISS operates a comprehensive, state-of-the-art MEMS fabrication facility located near Ann Arbor, Michigan. ISS is currently certified for ISO 9001:2008, EN13980:2002 for its ATEX (intrinsically safe products), and ISO13485:2003 standard for Class III medical devices. ISS is a vertically integrated company dedicated to developing and manufacturing system-level products based on MEMS technology (MEMS Inside), please visit: http://www.mems-issys.com/
Source: Integrated Sensing Systems, Inc. (ISS)
Nader Najafi, Ph.D.
Integrated Sensing Systems Inc. (ISS)
391 Airport Industrial Dr., Ypsilanti, MI 48198
Tel: (734) 547-9896 Ext. 103
Fax: (734) 547-9964